MediWound (NASDAQ:MDWD) and exclusive North America licensee Vericel (NASDAQ:VCEL) announce the submission of a U.S. marketing application seeking approval of NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
Vericel acquired the rights in May 2019 in an agreement valued up to $150M. MDWD will supply NexoBrid at a transfer price plus a fixed margin percentage.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.